Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation
Condition: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Intervention: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - Hôpitaux de Paris; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Neoadjuvant Therapy | Research